Search results
Psychedelic drug MDMA faces FDA panel in bid to become first-of-a-kind PTSD medication
Medical Xpress· 2 hours agoFederal health advisers are weighing the first-of-a-kind approval of MDMA, the mind-altering club...
FDA fast tracks Quince Therapeutics’ rare ataxia drug EryDex
Pharmaceutical Technology via Yahoo Finance· 8 hours agoCalifornia-based biotech Quince Therapeutics has won fast track designation from the US Food and...
FDA panel to review psychedelic drug MDMA for first time
Reuters· 8 hours agoThe meeting by the agency's independent experts is the farthest that a drug based on MDMA, commonly...
High Confidence AD Drug Donanemab Will Get FDA Panel Nod
Medscape· 14 hours agoThe Peripheral and Central Nervous System Drugs Advisory Committee of the US Food and Drug...
BAI, FDA in tieup to accelerate vaccine testing - BusinessWorld Online
BusinessWorld· 6 hours agoTHE Bureau of Animal Industry (BAI) and the Food and Drug Administration (FDA) signed a memorandum...
FDA reviews MDMA for PTSD treatment; Biden to issue executive order on border policy
NPR· 7 hours agoA panel of FDA experts starts reviewing clinical trial data today to decide whether to approve the...
Microbot’s LIBERTY robotic system secures FDA approval for pivotal trial
Medical Device Network via Yahoo Finance· 9 hours agoPre-clinical medical device company Microbot Medical has obtained US Food and Drug Administration (...
Cookie recall update as FDA inspection uncovers "serious violations"
Newsweek· 1 day agoThe FDA has issued a warning letter to a cookie manufacturer after their cookie dough product was...
Possible medical approval for MDMA discussed by FDA panel
New York Daily News· 2 hours agoMDMA, also known as molly or ecstasy, has been clinically tested as a possible treatment for PTSD, a mental health condition closely linked to depression, anxiety and suicidal thoughts. A panel ...
FDA selects Larimar Therapeutics for new program inspired by Operation Warp Speed - The Business...
The Business Journals· 8 hours agoNomlabofusp, an experimental therapy for Friedreich’s ataxia being developed by Larimar Therapeutics, was chosen for the FDA's Support for Clinical Trials Advancing Rare Disease ...
